Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for Europea...
October 04 2016 - 7:01AM
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug
discovery and development company advancing therapies for Duchenne
muscular dystrophy (‘DMD’) and Clostridium difficile infection,
announces that in conjunction with today’s announcement on an
exclusive license and collaboration agreement with Sarepta
Therapeutics for European rights to Summit’s utrophin modulator
pipeline for the treatment of DMD, Summit will be holding a
conference call at 1:00pm BST / 8:00am EDT.
To participate in the conference call, please
dial +44(0)20 3427 1918 (UK and international participants) or +1
646 254 3365 (US local number) and use the conference confirmation
code 6907795. Investors may also access a live audio webcast of the
call via the investors section of the Company’s website
www.summitplc.com. A replay of the webcast will be available
shortly after the presentation finishes.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programmes focused on the
genetic disease Duchenne muscular dystrophy and the infectious
disease C. difficile infection. Further information is available at
www.summitplc.com and Summit can be followed on Twitter
(@summitplc).
For more information, please contact:
Summit
Therapeutics |
|
Glyn Edwards
/ Richard Pye (UK office)Erik Ostrowski / Michelle
Avery (US office) |
Tel: +44
(0)1235 443 951 +1 617 225 4455 |
|
|
Cairn Financial
Advisers LLP |
|
(Nominated Adviser)Liam
Murray / Tony Rawlinson |
Tel: +44
(0)20 7148 7900 |
|
|
N+1
Singer |
|
(Broker)Aubrey Powell /
Jen Boorer |
Tel: +44
(0)20 7496 3000 |
|
|
MacDougall
Biomedical Communications |
|
(US media contact)Chris
Erdman / Karen Sharma |
Tel: +1 781
235 3060 cerdman@macbiocom.com ksharma@macbiocom.com |
|
|
Consilium
Strategic Communications |
|
(Financial public
relations, UK)Mary-Jane Elliott / Sue Stuart / Jessica Hodgson /
Lindsey Neville |
Tel: +44
(0)20 3709 5700summit@consilium-comms.com |
-END-
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Apr 2023 to Apr 2024